pharmaceutical daily news

Stada said Thursday it increases its indirect shareholding in the Vietnamese pharmaceutical company Pymepharco JSC to 72 percent, with a goal to expand in the one of the key growth markets in Asia.

Gilead’s company Kite’s trial for KTE-X19, its chimeric antigen receptor T cell therapy for adults with ALL (leukemia), resulted in high number of patients getting complete leukemia remission after a single infusion.

Bristol-Myers Squibb will transfer $3.8 billion of U.S. pension obligations through a full termination of its U.S. Retirement Income Plan. BMS said it will distribute the obligations through a combination of lump sums to Plan participants who elect such payments, and the purchase of a group annuity contract from Athene

AstraZeneca will divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal for uprfont payments of $815 million.

Novartis’s Biologics License Application (BLA) for Zolgensma, designed to tackle the genetic root cause of spinal muscular atrophy (SMA) Type 1, a deadly neuromuscular disease, was accepted by the U.S. Food and Drug Administration (FDA).

Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the National Medical Products Administration (NMPA), which is the first Helsinn cancer supportive care in China, which will be mareketed by Mundipharma China Pharmaceutical.

Shield Therapeutics said Monday that US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead product Feraccru.

Tiziana Life Sciences has completed patient enrollment in the ongoing Phase 2a clinical a single-arm, repeated-dose, 6-month duration study of Milciclib for certain patients with unresectable or metastatic HCC, with the topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019.